Latest on
Twitter
Latest
News & Views
- MLCSU collaboration project shortlisted for HSJ award
- Blog: ‘Might’ is right
- Blueprint to support ICS digital transformation
- Report: The case for surgical hubs
- MLCSU-supported finance team win award
- MLCSU director named HSJ100 wildcard for 2022
- Our experts at NHS ConfedExpo: Schedule announced
- MLCSU nominated for three NHS Health and Care Apprenticeship Awards
- We’re exhibiting at NHS ConfedExpo, 15-16 June
- Innovative NHS resource-booking system signs up 20th customer
- Blog: How can digital advances help a greener NHS?
- Blog: Why digital advances are so important to new hospitals
- 2021, our journey alongside ICS partners
- Blog: Treating people on waiting lists: who decides what is fair?
- Kicking off a study on menopause and the NHS workforce
Improving anti-coagulant prescribing in Warrington
Our review of anti-coagulant prescribing improved patient safety and reduced costs.
Background:
Direct oral anti-coagulants (DOAC) have now increased greatly as one treatment choice over the alternative warfarin. This is because they do not require the intense monitoring needed for warfarin. Patients on a DOAC will only require more routine monitoring once a year or every three months, depending on their renal function. Risks that need to be considered with taking a DOAC include under or over coagulation and continuing treatment for longer than necessary. It is important to check that those prescribed for atrial fibrillation (AF) are correctly read-coded to be on the AF register for their practice in order to ensure correct follow up.
Action:
In each Warrington practice, our MMO team conducted a review of all patients taking any of the four DOAC medicines currently prescribed across the CCG. They looked specifically at the risk factors with DOACs. These included indication, dose and duration of therapy, as patients may remain on the incorrect dose for the indication or a longer treatment length than necessary. Duration of treatment, and stop dates for courses, were documented in patient notes. Patients’ renal function and weight was reviewed for dose prescribed and amended as appropriate.
The team checked any drug interactions and also for appropriateness of medication for indication/risk factors ensuring the clinical indication was clearly documented by read code in the GP system.
For this project, the team created bespoke searches and numerical filters to show all existing values relating to DOAC monitoring.
Impact:
The DOAC review was started in March 2018 across 27 GP practices in Warrington. The table below shows the interventions that were made by the MMO team:
Number of Patients in total from Searches on DOAC | Number of patients currently on appropriate dose (at time of audit) | Average % patients on appropriate dose | Number of patients that require missing or appropriate Read code | Number of patients that require treatment stopping or a dose reduction | Number of patients that require dose increase |
2426 | 2059 | 85% | 116 (4.8%) | 114 (4.7%) | 21 (0.9%) |
In addition to the safety aspect of this work there were £9,000 cost savings made in total.